Mitsubishi Tanabe Pharma Domestic Sales Increase In April-September Quarter
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma's domestic prescription drug sales increased by 4.2 percent to ¥172.1 billion for the quarter, largely contributed by blockbuster monoclonal antibody rheumatoid arthritis drug Remicade (infliximab), which grew by 28 percent to ¥22.7 billion